Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review explores the potential of cell-mediated drug delivery systems in dermatology, highlighting their ability to target inflamed or diseased skin while discussing applications in diseases like atopic dermatitis and melanoma, along with challenges such as immunogenicity and manufacturing.

In this study, a transgenic mouse model was used to demonstrate that targeted cell loss in different tissues led to varying degrees of regenerative outcomes, including reversible impaired glucose tolerance, irreversible hair loss, and permanent moderate deafness.

The research found that hair follicle–derived cytokines, particularly IL-15 and IL-7, regulate skin-resident memory T cells and their role in both immune homeostasis and lymphoma in the skin.

This study found distinct gene expression profiles in alopecia areata-affected skin, suggesting T-cell mediated immune responses and unique gene profiles between different stages of the disease.

This study found that anti-CD44 treatment inhibited leukocyte migration in alopecia areata and eczema, suggesting targeted therapies could enhance contact sensitizer treatment for alopecia areata.

This narrative review discusses advancements in the understanding and treatment of dermatitis herpetiformis as a manifestation of celiac disease and reports no new research results.

This study suggests that targeting specific immune pathways, such as IL-12/23 and Th2 cytokines, may offer new treatment options for alopecia areata, a T-cell-mediated disease without current mechanism-specific therapies.

This case report describes a young adult female with late-stage Vogt-Koyanagi-Harada disease featuring panuveitis, retinal detachment, hearing loss, alopecia, and vitiligo, who was successfully treated in a hospital.

This study found that disrupting inflammasome signaling by eliminating caspase-1 and -11 in mice reduced skin inflammation and delayed the onset of disease, highlighting their role in skin disease pathogenesis.

This review indicates that mesenchymal stem cell therapy may offer clinical improvements for immune-mediated inflammatory skin diseases, showing promise particularly for those unresponsive to traditional treatments, but emphasizes the need for larger, controlled trials to confirm these results.

This study identified shared gene expression changes and immune cell infiltration patterns that may contribute to hair loss in alopecia areata and cutaneous lupus erythematosus, but also highlighted factors that might preserve hair in psoriasis patients.

This review discusses the roles of interferon-γ and PPAR-γ-mediated signalling in scarring alopecia, suggesting these pathways as potential therapeutic targets, but it reports no new empirical results.

This study found that patients with alopecia areata have lower levels of sCD83, a protein which, when supplemented in a mouse model, reversed disease symptoms and supported regulatory T cell proliferation, possibly by interacting with IDO activity.

This study reports that C3H/HeJ mice and DEBR rats serve as effective models for screening potential treatments for human alopecia areata, despite certain challenges in predictability and cost.

This review discusses rodent models of alopecia areata and suggests they are crucial for understanding the autoimmune mechanisms and potential treatments but reports no new clinical results.

This article discusses the diagnostic approach to focal alopecia in dogs, focusing on distinguishing between pruritic skin disease and inflammatory or non-inflammatory causes; it presents no new experimental results.

This review discusses the pathogenesis and challenges in treating primary cicatricial alopecia, highlighting the need to understand immune protection collapse in hair follicle stem cells; it reports no new clinical results.

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

In this case report, two plywood mill workers developed allergic contact dermatitis due to exposure to uncured phenol-formaldehyde resin, not sawdust as initially suspected.

Alopecia areata is caused by an immune response, and targeting immune cells might help treat it.

This review discusses the evidence supporting Janus kinase inhibitors for alopecia areata and highlights ongoing optimism as phase 3 trials begin, with no new clinical results reported.

This study reports that a 14-year-old female rhesus monkey with alopecia universalis was found to have a T-cell-mediated autoimmune disease similar to human alopecia areata universalis.

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results.

This report describes a case where an elderly woman developed alopecia areata shortly after receiving the Pfizer COVID-19 vaccine, which was effectively treated with topical tacrolimus and minoxidil.

This article reviews the autoimmune mechanism and potential environmental triggers of alopecia areata, focusing on cytokines, but does not provide new research findings.

This review examines the immunological aspects of alopecia areata, focusing on genetic, neuroimmunological, and immune privilege factors, but does not report new clinical findings.

This article discusses the phases and histological features of alopecia areata and reports no new clinical findings; the authors emphasize recognizing these phases for accurate diagnosis.

This review discusses current and potential treatments for alopecia areata, focusing on immunosuppressive and immunomodulatory approaches, but provides no new clinical results.

In this study, a 55-year-old man with a localized patch of alopecia areata achieved hair regrowth through intralesional triamcinolone acetonide injections, demonstrating this treatment as an effective initial therapy for localized alopecia areata.